Gilead Emtriva Marketing For HIV Will Highlight Long Intracellular Half-Life
Executive Summary
Gilead Sciences' is highlighting Emtriva's long intracellular half-life as a distinguishing feature in the nucleoside reverse transcriptase inhibitor market for HIV therapy
You may also be interested in...
GlaxoSmithKline, Gilead HIV Combos Clear FDA
GlaxoSmithKline will use a 60-day supply voucher program to help establish a patient base for its HIV-1 lamivudine/abacavir fixed-dose combination treatment Epzicom
GlaxoSmithKline, Gilead HIV Combos Clear FDA
GlaxoSmithKline will use a 60-day supply voucher program to help establish a patient base for its HIV-1 lamivudine/abacavir fixed-dose combination treatment Epzicom
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies